Maria Virginia Pascual

US Patent:

7622110, Nov 24, 2009

Filed:

Oct 26, 2007

Appl. No.:

11/925568

Inventors:

Jacques F. Banchereau - Dallas TX, US
Maria Virginia Pascual - Dallas TX, US

Assignee:

Baylor Research Institute - Dallas TX

International Classification:

A61K 39/395
A61K 38/20
C07K 14/545
C07K 14/715

US Classification:

4241301, 514 2, 514825, 530351, 5303871, 5303892

Abstract:

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e. g. , systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

US Patent:

20070134690, Jun 14, 2007

Filed:

Oct 6, 2006

Appl. No.:

11/544377

Inventors:

Maria Pascual - Dallas TX, US
Jacques Banchereau - Dallas TX, US
Damien Chaussabel - Richardson TX, US
Florence Allantaz - Richardson TX, US

Assignee:

Baylor Research Institute - Dallas TX

International Classification:

C12Q 1/68
G06F 19/00

US Classification:

435006000, 702020000

Abstract:

The present invention includes compositions, systems and methods for the early detection and consistent determination of systemic onset juvenile idiopathic arthritis (SoJIA) using microarrays.

US Patent:

20070238094, Oct 11, 2007

Filed:

Jun 5, 2006

Appl. No.:

11/446825

Inventors:

Damien Chaussabel - Richardson TX, US
Maria Pascual - Dallas TX, US
Jacques Banchereau - Dallas TX, US

Assignee:

Baylor Research Institute - Dallas TX

International Classification:

C12Q 1/70
C12Q 1/68
C12M 3/00

US Classification:

435005000, 435006000, 435287200

Abstract:

The present invention includes compositions, systems, arrays and methods for the early detection and consistent determination of SLE using modular analysis of gene expression data.

US Patent:

20080161262, Jul 3, 2008

Filed:

Oct 26, 2007

Appl. No.:

11/925538

Inventors:

Jacques F. Banchereau - Dallas TX, US
Maria Virginia Pascual - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

A61K 31/7105
A61K 31/713
A61P 19/02

US Classification:

514 44

Abstract:

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

US Patent:

20080161424, Jul 3, 2008

Filed:

Oct 26, 2007

Appl. No.:

11/925555

Inventors:

Jacques F. Banchereau - Dallas TX, US
Maria Virginia Pascual - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

A61K 45/00
A61P 19/02

US Classification:

514789

Abstract:

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

US Patent:

20080227709, Sep 18, 2008

Filed:

Mar 12, 2008

Appl. No.:

12/046874

Inventors:

Maria Virginia Pascual - Dallas TX, US
Jacques F. Banchereau - Dallas TX, US
Damien J. Chaussabel - Richardson TX, US
Ellen Kaizer - Dallas TX, US
Perrin C. White - Dallas TX, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 38/00
A61K 31/70
C12Q 1/68
C12Q 1/02
A61P 3/10
C40B 30/04
G01N 33/53

US Classification:

514 12, 514 44, 435 6, 435 29, 506 9, 435 792, 702 19

Abstract:

The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.

US Patent:

20100113293, May 6, 2010

Filed:

Sep 11, 2009

Appl. No.:

12/558334

Inventors:

Maria Virginia Pascual - Dallas TX, US
Jacques F. Banchereau - Dallas TX, US
Lynda B. Bennett - Columbia MO, US

Assignee:

BAYLOR RESEARCH INSTITUTE - Dallas TX

International Classification:

C40B 30/02
C40B 40/06

US Classification:

506 8, 506 16

Abstract:

The present invention provides compositions and methods for aiding in the diagnosis, monitoring and prognosis of SLE in a subject and for identifying potential therapeutic agents to treat and/or ameliorate the symptoms associated with SLE. Accordingly, embodiments of the invention are directed to methods of identifying the gene expression profile of a suitable sample by screening for the presence of a differentially expressed SLE-associated gene isolated from a sample containing or suspected of containing a cell that can differentially express an SLE-associated gene.

US Patent:

20110243938, Oct 6, 2011

Filed:

Sep 29, 2009

Appl. No.:

13/121680

Inventors:

Hideki Ueno - Dallas TX, US
Jacques F. Banchereau - Dallas TX, US
Maria Virginia Pascual - Dallas TX, US
Nathalie Schmitt - Dallas TX, US

Assignee:

Baylor Research Intitute - Dallas TX

International Classification:

A61K 39/395
C12N 5/0783
A61K 31/713
A61K 31/7088
A61P 3/10
A61P 19/02
A61P 7/06
A61P 25/00
A61P 29/00
A61P 37/06

US Classification:

4241331, 435377, 4241581, 4241451, 4241841

Abstract:

The present invention includes compositions and methods for the treatment of autoimmune diseases by administering to a subject having an autoimmune disorder an effective amount of a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one IL-12 inhibitor, e.g., a blocking anti-IL-12 antibody or fragment thereof.